Characteristics of the patients selected for biomarker analysis from the three data sources (the 24,152 patients ‘with relevant outcome data’ in figure 1A)
| Atezo* (N=3294) | CGDB† (N=2111) | FH‡ (N=18,747) | |
| Age§ | |||
| Mean (SD) | 63.2 (9.27) | 67.4 (9.93) | 68.1 (9.23) |
| Median (min, max) | 64.0 (25.0, 90.0) | 68.0 (27.0, 85.0) | 69.0 (25.0, 85.0) |
| Sex | |||
| Female | 1204 (36.6%) | 1095 (51.9%) | 8866 (47.3%) |
| Male | 2090 (63.4%) | 1016 (48.1%) | 9880 (52.7%) |
| Unknown | 0 (0%) | 0 (0%) | 1 (0.0%) |
| Race | |||
| African American | 65 (2.0%) | 146 (6.9%) | 1713 (9.1%) |
| Asian | 583 (17.7%) | 66 (3.1%) | 383 (2.0%) |
| Caucasian | 2525 (76.7%) | 1477 (70.0%) | 13,762 (73.4%) |
| Other | 20 (0.6%) | 299 (14.2%) | 1507 (8.0%) |
| Unknown | 101 (3.1%) | 123 (5.8%) | 1382 (7.4%) |
| ECOG PS¶ | |||
| 0 | 1300 (39.5%) | 577 (27.3%) | 4219 (22.5%) |
| 1 | 1983 (60.2%) | 1037 (49.1%) | 6865 (36.6%) |
| 2 | 8 (0.2%) | 267 (12.6%) | 2329 (12.4%) |
| 3 | 1 (0.0%) | 60 (2.8%) | 483 (2.6%) |
| 4 | 0 (0%) | 2 (0.1%) | 28 (0.1%) |
| Missing | 2 (0.1%) | 168 (8.0%) | 4823 (25.7%) |
| Disease stage** | |||
| Stage 0 | 0 (0%) | 0 (0%) | 2 (0.0%) |
| Stage I | 247 (7.5%) | 190 (9.0%) | 1598 (8.5%) |
| Stage II | 251 (7.6%) | 148 (7.0%) | 1027 (5.5%) |
| Stage III | 616 (18.7%) | 525 (24.9%) | 4808 (25.6%) |
| Stage IV | 2125 (64.5%) | 1201 (56.9%) | 10,732 (57.2%) |
| Unknown | 55 (1.7%) | 47 (2.2%) | 580 (3.1%) |
| Smoking history | |||
| Previous/current | 2763 (83.9%) | 1775 (84.1%) | 16 672 (88.9%) |
| Never | 531 (16.1%) | 333 (15.8%) | 1902 (10.1%) |
| Unknown | 0 (0%) | 3 (0.1%) | 173 (0.9%) |
| Histology | |||
| Non-squamous | 2404 (73.0%) | 1560 (73.9%) | 12,633 (67.4%) |
| Squamous | 848 (25.7%) | 484 (22.9%) | 5258 (28.0%) |
| Unknown | 42 (1.3%) | 67 (3.2%) | 856 (4.6%) |
*Atezo—atezolizumab NSCLC trials.
†CGDB—Clinico-Genomic Database by Flatiron Health-Foundation Medicine.
‡FH—Flatiron Health electronic health record database.
§Age—age at treatment start.
¶ECOG PS—baseline Eastern Cooperative Oncology Group performance status before treatment start.
**Disease stage—group stage at initial diagnosis for the RWD sources (FH and CGDB), and at study start for the atezolizumab trials.
NSCLC, non-small cell lung cancer ; RWD, real-world data.